Wedbush analyst David Nierengarten maintained a Hold rating on Bluebird Bio (BLUE) on June 14 and set a price target of $131. The company’s shares opened today at $126.12.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 25.1% and a 50.0% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Stemline Therapeutics Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $152.43, which is a 20.9% upside from current levels. In a report issued on June 14, Cantor Fitzgerald also maintained a Hold rating on the stock with a $124 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $189.31 and a one-year low of $87.49. Currently, Bluebird Bio has an average volume of 470.1K.
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is neutral on the stock. Last month, Jason Cole, the Chief Operating and of BLUE bought 562 shares for a total of $28,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
